FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080972893> ?p ?o ?g. }

• W2080972893 endingPage "437" @default.
• W2080972893 startingPage "A" @default.
• W2080972893 abstract "Background: Proton pump inhibitors (PPI) are the drug of first choice for treating patients with gastroesophageal reflux disease (GERD). However, about 50% of non-erosive reflux disease (NERD) patients have a poor response to PPI treatment. It is reported that esophageal motility disorder involving a decline in esophageal clearance contributes to the poor PPI response. Accordingly, a drug capable of enhancing esophageal motility would be beneficial in the treatment of NERD patients. Rikkunshito, a gastrointestinal prokinetic agent, is known to improve esophageal clearance in GERD patients and gastric emptying in functional dyspepsia patients and to increase secretion of ghrelin in rats. Aim: To clarify the efficacy of rikkunshito in NERD patients, we evaluated the effects of rikkunshito on esophageal and lower esophageal sphincter (LES) motility and symptoms. Methods: Fifteen patients were enrolled in the study. They were diagnosed as having NERD according to endoscopic testing and the score (6 points or more) obtained on the questionnaire for the diagnosis of reflux disease (QUEST). All patients stopped taking all gastrointestinal-related drugs for over 1 week prior to rikkunshito treatment, and were administered rikkunshito (7.5 g per day, orally) for 8 weeks. Esophageal and LES functions during liquid or semisolid swallow were evaluated using MII-EM following gold standard methods before and after rikkunshitotreatment. Symptoms were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) before, 4 weeks after, and 8 weeks after treatment. Results: Rikkunshito-treatment significantly improved the mean of complete bolus transit (CBT) during liquid or semisolid swallow from 60.7±7.7% to 90.0±5.8% (p 79%, semisolid: >69%) for CBT decreased from 53.3% to 16.7% and from 60.0% to 33.3% after treatment, respectively. In manometry evaluation, rikkunshito significantly improved the mean of LES residual pressure during liquid swallow from 6.0±1.3 mmHg to 3.8±1.4 mmHg (p<0.05). In addition, rikkunshito significantly ameliorated total GI symptom scores in GSRS (from 2.1±0.2 to 1.6±0.1: (p<0.05)) and showed a tendency toward improvement of subscales for reflux symptoms, abdominal pain and dyspeptic symptoms. Conclusion: We found that rikkunshito improved the esophageal clearance and symptoms in NERD patients through the amelioration of esophageal and LES motility disorder. Thus, rikkunshito may become a useful drug for treating NERD patients." @default.
• W2080972893 created "2016-06-24" @default.
• W2080972893 creator A5011282315 @default.
• W2080972893 creator A5029261529 @default.
• W2080972893 creator A5030431142 @default.
• W2080972893 creator A5049021663 @default.
• W2080972893 creator A5061327780 @default.
• W2080972893 creator A5072973626 @default.
• W2080972893 creator A5075842010 @default.
• W2080972893 date "2009-05-01" @default.
• W2080972893 modified "2023-10-16" @default.
• W2080972893 title "M1876 Rikkunshito Improves Esophageal Motility Disorder and Symptoms in Patients with NERD - a Study Using Combined Multichannel Intraluminal Impedance and Manometry (MII-EM) -" @default.
• W2080972893 doi "https://doi.org/10.1016/s0016-5085(09)62011-4" @default.
• W2080972893 hasPublicationYear "2009" @default.
• W2080972893 type Work @default.
• W2080972893 sameAs 2080972893 @default.
• W2080972893 citedByCount "0" @default.
• W2080972893 crossrefType "journal-article" @default.
• W2080972893 hasAuthorship W2080972893A5011282315 @default.
• W2080972893 hasAuthorship W2080972893A5029261529 @default.
• W2080972893 hasAuthorship W2080972893A5030431142 @default.
• W2080972893 hasAuthorship W2080972893A5049021663 @default.
• W2080972893 hasAuthorship W2080972893A5061327780 @default.
• W2080972893 hasAuthorship W2080972893A5072973626 @default.
• W2080972893 hasAuthorship W2080972893A5075842010 @default.
• W2080972893 hasConcept C126322002 @default.
• W2080972893 hasConcept C2777014526 @default.
• W2080972893 hasConcept C2777683962 @default.
• W2080972893 hasConcept C2778510232 @default.
• W2080972893 hasConcept C2779134260 @default.
• W2080972893 hasConcept C2780942740 @default.
• W2080972893 hasConcept C43270747 @default.
• W2080972893 hasConcept C71924100 @default.
• W2080972893 hasConcept C90924648 @default.
• W2080972893 hasConceptScore W2080972893C126322002 @default.
• W2080972893 hasConceptScore W2080972893C2777014526 @default.
• W2080972893 hasConceptScore W2080972893C2777683962 @default.
• W2080972893 hasConceptScore W2080972893C2778510232 @default.
• W2080972893 hasConceptScore W2080972893C2779134260 @default.
• W2080972893 hasConceptScore W2080972893C2780942740 @default.
• W2080972893 hasConceptScore W2080972893C43270747 @default.
• W2080972893 hasConceptScore W2080972893C71924100 @default.
• W2080972893 hasConceptScore W2080972893C90924648 @default.
• W2080972893 hasIssue "5" @default.
• W2080972893 hasLocation W20809728931 @default.
• W2080972893 hasOpenAccess W2080972893 @default.
• W2080972893 hasPrimaryLocation W20809728931 @default.
• W2080972893 hasRelatedWork W1981437669 @default.
• W2080972893 hasRelatedWork W1986415718 @default.
• W2080972893 hasRelatedWork W2340735469 @default.
• W2080972893 hasRelatedWork W2366087390 @default.
• W2080972893 hasRelatedWork W2384301141 @default.
• W2080972893 hasRelatedWork W2415949661 @default.
• W2080972893 hasRelatedWork W2922144439 @default.
• W2080972893 hasRelatedWork W2978141775 @default.
• W2080972893 hasRelatedWork W3029294019 @default.
• W2080972893 hasRelatedWork W3148573169 @default.
• W2080972893 hasVolume "136" @default.
• W2080972893 isParatext "false" @default.
• W2080972893 isRetracted "false" @default.
• W2080972893 magId "2080972893" @default.
• W2080972893 workType "article" @default.